Print this page

AP & T 1 March 2017

AP&T: CONTENTS LISTING FOR THE 1st MARCH 2017 ISSUE

The contents listing for the 1st March 2017 issue of Alimentary Pharmacology & Therapeutics is listed below and, as a member of the New Zealand Society of Gastroenterology, you have free access to all these articles when you log-in via the Members’ Area of the NZSG website - www.nzsg.org.nz

Yours sincerely

Roy

Professor R E Pounder
Co-Editor
Alimentary Pharmacology & Therapeutics
website: www.APandT.org
Follow AP&T on Twitter: @APandT

------------------------------------------------------------------------------------------------------

CONTENTS LIST FOR 1st MARCH 2017 ISSUE OF
ALIMENTARY PHARMACOLOGY & THERAPEUTICS



SYSTEMATIC REVIEWS WITH META-ANALYSES

Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm (pages 581–592)
J. P. Segal, N. S. Ding, G. Worley, S. Mclaughlin, S. Preston, O. D. Faiz, S. K. Clark and A. L. Hart

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 (pages 593–603)
F. J. Gifford, J. R. Morling and J. A. Fallowfield

Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth (pages 604–616)
L. Gatta and C. Scarpignato


REVIEW ARTICLE

Review article: dose optimisation of infliximab for acute severe ulcerative colitis (pages 617–630)
P. Hindryckx, G. Novak, N. Vande Casteele, D. Laukens, C. Parker, L. M Shackelton, N. Narula, R. Khanna, P. Dulai, B. G Levesque, W. J Sandborn, G. D'Haens, B. G. Feagan and V. Jairath


RANDOMISED CLINICAL TRIAL

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation (pages 631–642)
V. Savarino, F. Pace, C. Scarpignato and for the Esoxx Study Group


COELIAC DISEASE

Serum alkylresorcinols as biomarkers of dietary gluten exposure in coeliac disease (pages 643–652)
R. S. Choung, J. A. Murray, E. V. Marietta, C. T. Van Dyke and A. B. Ross


INFLAMMATORY BOWEL DISEASE

Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases (pages 653–659)
R. W. Winter, E. Collins, B. Cao, M. Carrellas, A. M. Crowell and J. R. Korzenik

Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease (pages 660–669)
N. Heerasing, B. Thompson, P. Hendy, G. A. Heap, G. Walker, R. Bethune, S. Mansfield, C. Calvert, N. A. Kennedy, T. Ahmad and J. R. Goodhand


ADAPTATION OF COLONIC MICROBIOTA TO GALATOOLIGOSACCHARIDES

Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proof-of-concept-study (pages 670–680)
M. Mego, C. Manichanh, A. Accarino, D. Campos, M. Pozuelo, E. Varela, J. Vulevic, G. Tzortzis, G. Gibson, F. Guarner and F. Azpiroz


HEPATITIS C

Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt (pages 681–687)
A. Elsharkawy, R. Fouad, W. El Akel, M. El Raziky, M. Hassany, G. Shiha, M. Said, I. Motawea, T. El Demerdash, S. Seif, A. Gaballah, Y. El Shazly, M. A. M. Makhlouf, I. Waked, A. O. Abdelaziz, A. Yosry, M. El Serafy, M. Thursz, W. Doss and G. Esmat

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection (pages 688–700)
M. Cornberg, J. Petersen, A. Schober, S. Mauss, K. H. W. Böker, R. Link, R. Günther, Y. Serfert, H. Pfeiffer-Vornkahl, M. P. Manns, C. Sarrazin, D. Hüppe, T. Berg and C. Niederau


HEPATITIS E

Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection (pages 701–713)
S. Zhang, C. Chen, J. Peng, X. Li, D. Zhang, J. Yan, Y. Zhang, C. Lu, J. Xun, W. Li, Y. Ling, Y. Huang and L. Chen


HEPATIC RESERVE POST-SORAFENIB FAILURE

The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development (pages 714–722)
D. J. Pinato, C. Yen, D. Bettinger, R. Ramaswami, T. Arizumi, C. Ward, M. Pirisi, M. E. Burlone, R. Thimme, M. Kudo and R. Sharma


EXPERT CLINICAL MANAGEMENT OF AUTOIMMUNE HEPATITIS

Expert clinical management of autoimmune hepatitis in the real world (pages 723–732)
R. Liberal, Y. S. de Boer, R. J. Andrade, G. Bouma, G. N. Dalekos, A. Floreani, D. Gleeson, G. M. Hirschfield, P. Invernizzi, M. Lenzi, A. W. Lohse, G. Macedo, P. Milkiewicz, B. Terziroli, B. van Hoek, J. M. Vierling, M. A. Heneghan and on behalf of the International Autoimmune Hepatitis Group (IAIHG)


SCORING PROGNOSIS IN PRIMARY BILIARY CHOLANGITIS

The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210 (pages 733–743)
F. Yang, Y. Yang, Q. Wang, Z. Wang, Q. Miao, X. Xiao, Y. Wei, Z. Bian, L. Sheng, X. Chen, D. Qiu, J. Fang, R. Tang, M. E. Gershwin and X. Ma


LIVER BIOPSY WITH KLATSKIN NEEDLES

Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience (pages 744–753)
V. Takyar, O. Etzion, T. Heller, D. E. Kleiner, Y. Rotman, M. G. Ghany, N. Fryzek, V. H. Williams, E. Rivera, S. Auh, T. J. Liang, J. H. Hoofnagle and C. Koh


INVITED EDITORIALS

Editorial: improving in-hospital management of decompensated cirrhosis by a ‘care bundle’ – hope, frustration, and lessons to learn (pages 754–755)
J. Bosch

Editorial: improving in-hospital management of decompensated cirrhosis by a ‘care bundle’ – hope, frustration and lessons to learn. Authors’ reply (pages 755–756)
S. McPherson, J. K. Dyson and M. Hudson


LETTERS TO THE EDITORS

Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer? (pages 757–758)
J.-F. Jiang, J. Sun, J. Shi and X. Liu

Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer? Authors’ reply (pages 758–759)
M. P. Economides, T. L. Shigle and H. A. Torres

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? (pages 759–760)
K. Bendtzen and C. Steenholdt

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply (pages 760–762)
S. Ben-Horin, B. Ungar and X. Roblin

Letter: causes of fatigue in inflammatory bowel disease remain uncertain (pages 762–763)
D. J. Gracie and A. C. Ford

Letter: causes of fatigue in inflammatory bowel disease remain uncertain – authors’ reply (pages 763–764)
M. Artom, W. Czuber-Dochan and C. Norton

Letter: more studies are needed to elucidate any association between Helicobacter pylori infection and Barrett's metaplasia (pages 764–765)
A. Talebi Bezmin Abadi

Letter: can transient elastography and body mass index predict fibrosis regression in HBV patients on long-term nucleoside therapy? (pages 765–766)
M. Barone, E. Shahini and A. Di Leo


Previous page: NZSG Secretariat
Next page: AP & T 15 March 2017